Compare TBPH & MEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | MEG |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | 3500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 930.8M |
| IPO Year | 2013 | 2020 |
| Metric | TBPH | MEG |
|---|---|---|
| Price | $13.86 | $22.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $18.50 | ★ $35.25 |
| AVG Volume (30 Days) | ★ 782.6K | 449.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.69 |
| EPS | ★ 0.88 | N/A |
| Revenue | $15,386,000.00 | ★ $830,538,000.00 |
| Revenue This Year | $70.90 | $4.94 |
| Revenue Next Year | N/A | $7.71 |
| P/E Ratio | $15.75 | ★ N/A |
| Revenue Growth | N/A | ★ 19.26 |
| 52 Week Low | $7.90 | $10.51 |
| 52 Week High | $21.03 | $32.00 |
| Indicator | TBPH | MEG |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 35.15 |
| Support Level | $13.41 | $21.00 |
| Resistance Level | $14.76 | $24.03 |
| Average True Range (ATR) | 0.58 | 1.34 |
| MACD | -0.08 | -0.58 |
| Stochastic Oscillator | 11.29 | 0.00 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.